全鞍区对比靶向立体定向放射外科治疗肢端肥大症:多中心匹配队列研究
该多中心回顾性匹配队列研究纳入1990至2016年10家中心的128例肢端肥大症患者,比较全鞍区与靶向立体定向放射外科(SRS)的疗效与安全性。两组生化缓解、复发、新发垂体功能减退及新发脑神经病变率相似,全鞍区组肿瘤退缩率更高、死亡和新发视野缺损率更高但无统计学显著性。作者提出靶向SRS或可优先考虑,需进一步研究视野缺损与死亡的关联。
要点
- 全鞍区与靶向SRS的生化缓解和复发率无差异。
- 全鞍区组肿瘤退缩率更高,但死亡和新发视野缺损率也更高(未达统计学显著)。
- 结果提示肢端肥大症治疗可考虑优先选择靶向SRS。
核心结论
- 全鞍区与靶向SRS在生化缓解或复发方面无差异。
- 全鞍区SRS的肿瘤退缩率更高、死亡和新发视野缺损率更高,但均无统计学显著性,提示可考虑优先选择靶向SRS。
研究设计与样本
- 多中心、回顾性、1:1匹配队列研究,纳入1990至2016年10家国际放射外科研究基金会中心共128例接受SRS的肢端肥大症患者。
主要发现
- 全鞍区组SRS前随机血清生长激素更高、治疗体积更大、视路最大点剂量更高。
- 两组初始/持久内分泌缓解、新发垂体功能丧失及新发脑神经病变率相似。
- 全鞍区组死亡和新发视野缺损率更高,但无统计学显著性。
关键数值与推荐
- 全鞍区与靶向SRS患者按1:1比例匹配。
临床怎么用
- 在肢端肥大症SRS治疗中,可考虑优先选择靶向SRS而非全鞍区SRS。
局限性
- 为回顾性研究,全鞍区组基线生长激素更高、治疗体积更大、视路最大点剂量更高。
- 死亡和新发视野缺损与全鞍区SRS的关联尚需进一步研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted stereotactic radiosurgery (SRS) with sparing of the residual pituitary is the traditional radiosurgical method for pituitary adenomas. Whole-sella SRS is an alternative choice for radiologically indeterminate or large adenomas, the safety and efficacy of which has yet to be determined. OBJECTIVE: To determine if whole-sella SRS in acromegaly would have comparable radiographic and biochemical control to targeted SRS. We performed a multicenter, retrospective matched cohort study to compare outcomes between groups. METHODS: We conducted a retrospective review of acromegalic patients who underwent SRS from 1990 to 2016 at 10 centers participating in the International Radiosurgery Research Foundation. Whole-sella and targeted SRS patients were then matched in a 1:1 ratio. RESULTS: A total of 128 patients were eligible for inclusion. Whole-sella patients had a higher pre-SRS random serum growth hormone, larger treatment volume, and higher maximum point dose to the optic apparatus. The rates of initial/durable endocrine remission, new loss of pituitary function, and new cranial neuropathy were similar between groups. Mortality and new visual deficit were higher in the whole-sella cohort, though not statistically significant. CONCLUSION: There was no difference in biochemical remission or recurrence between treatment groups. Although not statistically significant, the higher rates of tumor regression and lower rates of mortality and new visual deficit may suggest consideration of targeted SRS over whole-sella SRS in acromegaly treatment. Further research is needed to determine the association between visual deficits and mortality with whole-sella SRS.
引用
- Taylor DG, Janssen A, Ding D, et al. Whole Sella vs Targeted Stereotactic Radiosurgery for Acromegaly: A Multicenter Matched Cohort Study. Neurosurgery. 2020. PMID: 31384920. doi:10.1093/neuros/nyz245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。